These include: Semaglutide (Wegovy) recommended by NICE for weight management in eligible adults (NICE TA875) Liraglutide (Saxenda) recommended by NICE for weight management in selected groups (NICE TA664) Orlistat available for weight management under NICE guidance (NICE CG189) Naltrexone/bupropion (Mysimba) does not currently have a positive NICE recommendation for weight management in England and should not be assumed to be a routinely recommended option
TRIUMPH-1 Phase 3 Trials: Breakthrough Results The TRIUMPH-1 Phase 3 clinical trials revealed groundbreaking results, offering hope to those in Skokie looking for effective weight loss solutions
But I told myself, Even if I lose 10 pounds, I will feel better
In 2025, Novo Nordisks semaglutide awaits several first-time FDA decisions: Injectable GLP-1s 2025 Ozempic for T2DM and peripheral artery disease (PAD) 2H 2025 Wegovy for heart failure with preserved ejection fraction (HFpEF) and obesity Oral GLP-1s October 2025 new indication for oral Rybelsus for secondary CV risk reduction 4Q 2025 the first oral GLP-1 ( oral formulation of Wegovy 25 mg ) for weight loss and weight loss plus secondary CV risk reduction Given the considerable continued growth expected in the GLP-1 pipeline, Prime Therapeutics (Prime) talented team of clinical experts actively monitors this emerging landscape
Remember, adding GLP-1 is not a sign of failure, but an effective, evidence-based tool to aid significant, durable weight loss
In the interim, it should be appreciated that several instruments have been used widely in the evaluation of symptoms associated with GI disorders, including the Bowel Disease Questionnaire (BDQ) (29), a comprehensive questionnaire with 71 precisely defined questions
